Use of metformin in obese adolescents with hyperinsulinemia: A 6-month, randomized, double-blind, placebo-controlled clinical trial

Journal of Pediatric Endocrinology and Metabolism

Volumn 21, Issue 4, 2008, Pages 339-348

  Atabek, Mehmet Emre ^a   Pirgon, Ozgur ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Childhood obesity; Insulin sensitivity; Metformin; Weight loss

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; TRIACYLGLYCEROL;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BEHAVIOR THERAPY; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPERINSULINISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; METABOLIC SYNDROME X; OBESITY; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 44949253252     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2008.21.4.339     Document Type: Article

References (32)

1. Invitti C, Guzzaloni G, Gilardini L, Morabito F, Viberti G. Prevalence and concomitants of glucose intolerance in European obese children and adolescents. Diabetes Care 2003; 26: 118-124.
2. De Fronzo RA, Ferranini E. Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic cardio-vascular disease. Diabetes Care 1991; 14: 173-194.
3. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
4. Freemark M. Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J Clin Endocrinol Metab 2003; 88: 3-13.
5. Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab 2004; 89: 2526-2539.
6. Decsi T, Molnar D. Insulin resistance syndrome in children: pathophysiology and potential management strategies. Pediatr Drugs 2003; 5: 291-299.
7. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, Zimmet P, Defronzo RA, eds. International Textbook of Diabetes Mellitus, 2nd Ed. Chichester: John Wiley and Sons Ltd, 1997; 841-864.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
9. Mehnert H. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001; 109: 259-264.
10. Abbasi F, Carantoni M, Chen YD, Reaven GM. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care 1998; 21: 1301-1305.
11. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwege E. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996; 19: 920-926.
12. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001; 50: 2444-2450.
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985; 28: 412-419.
15. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
16. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997; 54: 801-808.
17. Sigal RJ, El-Hashimy M, Martin BC, Soeldner JS, Krolewski AS, Warram JH. Acute postchallenge hyper-insulinemia predicts weight gain: a prospective study. Diabetes 1997; 46: 1025-1029.
18. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990; 113: 909-915.
19. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyper-insulinemia. Diabetes 2000; 49: 2094-2101.
20. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinsson MJ. Effect of metformin in pediatric patients with type 2 diabetes. Diabetes Care 2002; 25: 89-94.
21. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: e55.
22. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normo-glycemic morbidly obese adolescents. Metabolism 2001; 50: 1457-1461.
23. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
24. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-422.
25. Laakso M, Sarlund H, Mykkanen L. Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 1990; 10: 223-231.
26. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002; 13: 17-30.
27. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 182-188.
28. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwege E. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19: 920-926.
29. Silverstein JH, Rosenbloom AL. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2000; 13: 1403-1409.
30. Zuhri-Yafi MI, Brosnan PG, Hardin DS. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2002; 15: 541-546.
31. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith LN. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29: 160-169.
32. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.